In a cohort of 27 DLBCL patients, only 1 patient (3.7%) with a frameshift mutation in TET2 was detected, suggesting a low mutation rate in DLBCL patients [31]. This evidence concerns the gene TET2 and diffuse large B-cell lymphoma.